| Filed On | Filing |
|---|---|
| 04 Aug 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities
On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategi... |
| 23 Jan 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On January 23, 2026 (the “Closing Date”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”) completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “Merger Agreemen... |
| 04 Sep 2018 |
8-K/A: Other Events
CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks |
| 04 Aug 2011 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
Please note that the following press release contains corrections to the net operating cash use |
| 02 May 2006 |
8-K/A: Entry into a Material Definitive Agreement
NOTE: THIS DOCUMENT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. PORTIONS OF THIS DOCUMENT FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED HAVE BEEN REDACTED AND... |
| 22 Dec 2005 |
8-K/A: Entry into a Material Definitive Agreement
NOTE: THIS DOCUMENT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. PORTIONS OF THIS DOCUMENT FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED HAVE BEEN REDACTED AND... |
| 02 Aug 1996 |
8-K/A: Other Events
Date of Report (Date of earliest event reported) May 3, 1996 ------------------------------- |
Loading...